BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing BriaCell has successfully completed its Phase I safety and tole

Announces Successful Completion of Phase I Portion of

Clinical Study in Advanced Breast Cancer; Randomized Phase II

PA and VANCOUVER, British Columbia, October 21, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"

or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased

to announce the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT , in combination with Incyte's

PD-1 inhibitor, retifanlimab, in advanced breast cancer. The efficacy and survival data of the treated patients is being evaluated in

the Phase II part of the study which was recently awarded the FDA's fast track designation. Under an FDA approved protocol, another

arm has recently been added to the Phase II study to evaluate the effects of dosing schedules for patients in the study.

are very impressed by the clinical data showing a favorable safety profile for our treatment in advanced breast cancer patients who have

failed other therapies," commented Dr. Del Priore, BriaCell's Chief Medical Officer. "We look forward to further advancing

this program and sharing the data in the coming months."

Phase I portion of the trial, with the primary goal of assessing safety and tolerability of the combination, enrolled 12 subjects who

had previously failed at least two prior lines of therapy, characterized as a difficult-to-treat patient population. The combination

treatment had a favorable safety profile and appeared well-tolerated with no dose-limiting toxicities.

progressing through the Phase II part of the clinical trial, a randomized controlled design will be used to allow comparison of the effectiveness

of the treatment regimens between the two arms of the study with different dosing schedules.

is on schedule to meet with the FDA later this year to discuss the design of a key registration study.

BriaCell Therapeutics Corp.

is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information

is available at https://briacell.com/.

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes

regarding the completion of the Phase II portion of the study; the potential success of the Bria-IMT program; the effect(s) of

Bria-IMT on patients;; the ability of the Company to further advance its clinical study; and the nature and frequency of communications

with the FDA. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties,

risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future

events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks

and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk

Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's

other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available

under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained

in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as

required under applicable law.

Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts

responsibility for the adequacy or accuracy of this release.